What did the FDA say about the Wegovy advertisement?

The FDA stated that the television advertisement for Wegovy was false or misleading, indicating it inaccurately portrayed the drug's benefits and advancements.

Why was the Wegovy ad considered misleading by the FDA?

The ad misleadingly suggested Wegovy's pill form was an advancement over other GLP-1 drugs and implied unproven emotional benefits beyond physical weight loss.

What action did the FDA request from Novo Nordisk?

The FDA requested that Novo Nordisk take immediate action to address any violations of the Federal Food, Drug, and Cosmetic Act related to the advertisement.

Home / Health / FDA Slams Wegovy Ad as Misleading

FDA Slams Wegovy Ad as Misleading

9 Feb

•

Summary

FDA found a Wegovy TV ad misleading regarding its pill form.
Ad falsely implied superior weight loss compared to other GLP-1s.
Regulator cited broader emotional and life benefits claims as unsubstantiated.

The U.S. Food and Drug Administration (FDA) has issued a strong statement regarding a television advertisement for Novo Nordisk's weight-loss pill, Wegovy. In a letter dated February 5, the health regulator deemed the advertisement "false or misleading."

The FDA specifically noted that the television spot misleadingly implied that Wegovy, in its pill form, represented an improvement over other drugs within the GLP-1 class. Claims such as "live lighter" were flagged as suggesting greater weight loss than has been scientifically demonstrated compared to existing GLP-1 treatments.

Furthermore, the agency highlighted that the advertisement insinuated benefits extending beyond physical weight loss, such as emotional relief and hope. The FDA stated these broader life benefit claims were not demonstrated and positioned the drug inappropriately as a solution for general life challenges rather than a specific medical treatment.